论文部分内容阅读
骨质疏松是绝经后妇女的常见病。雌激素替代疗法除能解除绝经后综合征外,还可防治骨质疏松,但长期应用可能增加子宫内膜病变或乳腺癌的危险性。而雷洛昔酚(Ra)是雌激素受体调节剂,对骨与血脂代谢影响与雌激素相同,有良好作用。而对子宫内膜与乳腺与雌激素不同,有拮抗作用。为比较结合雌激素(CEE)与Ra在短期内对骨组织形态学,骨密度(BMD)与骨转换生化指标的影响。对51例55～85岁至少绝经5年的妇女用Ra 60mg/d,或CEE 0.625mg/
Osteoporosis is a common disease in postmenopausal women. In addition to estrogen replacement therapy can relieve postmenopausal syndrome, but also prevent osteoporosis, but long-term use may increase the risk of endometrial lesions or breast cancer. Raloxifene (Ra), an estrogen receptor modulator, has the same effect on bone and blood lipid metabolism as estrogen and has a good effect. The endometrium and breast and estrogen are different, have antagonistic effect. To compare the effect of combined estrogen (CEE) and Ra on bone histomorphometry, bone mineral density (BMD) and biochemical markers of bone turnover in a short period of time. 51 patients 55 to 85 years of age at least five years of menopausal women with Ra 60mg / d, or CEE 0.625mg /